Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Aurora A kinase inhibitor LY3295668

An orally bioavailable inhibitor of the serine/threonine protein kinase aurora A, with potential antimitotic and antineoplastic activities. Upon administration, aurora A kinase inhibitor LY3295668 targets, binds to and inhibits the activity of aurora A kinase. This may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, inhibition of cell division and the induction of apoptosis in cells overexpressing aurora A kinase. Aurora A kinase, overexpressed in a wide variety of cancers, plays an essential role in the regulation of spindle assembly and mitosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:AK 01 erbumine
aurora kinase A inhibitor LY3295668 erbumine
LY 3295668 erbumine
LY-3295668 erbumine
LY3295668 erbumine
Code name:AK 01
AK-01
LY 3295668
LY-3295668
LY3295668
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search